Christopher Lischer, Martin Eberhardt, Cindy Flamann, Johannes Berges, Esther Güse, Anja Wessely, Adrian Weich, Jimmy Retzlaff, Jan Dörrie, Niels Schaft, Manuel Wiesinger, Johannes März, Beatrice Schuler-Thurner, Harald Knorr, Shailendra Gupta, Krishna Pal Singh, Gerold Schuler, Markus Vincent Heppt, Elias Andreas Thomas Koch, Nadine D van Kleef, Julian J Freen-van Heeren, Annelies W Turksma, Olaf Wolkenhauer, Bettina Hohberger, Carola Berking, Heiko Bruns, Julio Vera
BACKGROUND: Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline would lay the foundation for immunotherapy trials with the potential to enhance treatment, tremendously benefiting patients suffering from rare, understudied cancers. METHODS: We present an experimentally validated, data-driven computational pipeline that selects and ranks antigens in a multipronged approach...
May 9, 2024: Journal for Immunotherapy of Cancer